EvaluatePharma：2014年在研药物Top18
(2014-06-26 22:08:03)
|
新药
|
靶点
|
适应症
|
研发企业
|
状态
|
2020年销售额（单位：亿美元）
|
|
Nivolumab
|
Anti-PD1单抗
|
肿瘤
|
BMS
|
Phase III
|
60.12
|
|
MK-3475
|
Anti-PD1单抗
|
肿瘤
|
Merck
|
Filed
|
40.63
|
|
INT-747
|
FXR激动剂
|
脂肪肝
|
Intercept
|
Phase III
|
29.92
|
|
Palbociclib
|
CDK4/6抑制剂
|
HER2阴性乳腺癌
|
Pfizer
|
Phase III
|
29.50
|
|
RG7446
|
Anti-PDL1单抗
|
肿瘤
|
Roche
|
Phase III
|
29.37
|
|
Ledipasvir/Sofosbuvir
|
NS5A/NS5B抑制剂
|
HCV感染
|
Gilead
|
Filed
|
28.18
|
|
DCVax-L
|
癌症疫苗
|
肿瘤
|
Northwest
|
Phase III
|
20.46
|
|
VX-809/ ivacaftor
|
CFTR矫正剂
|
囊性纤维化
|
Vertex
|
Phase III
|
19.00
|
|
LCZ696
|
ARNI抑制剂
|
心力衰竭
|
Novartis
|
Phase III
|
13.29
|
|
Idelalisib
|
PI3K抑制剂
|
慢性淋巴细胞白血病
|
Gilead
|
Filed
|
12.73
|
|
Lampalizumab
|
Anti-Factor D单抗
|
年龄相关性黄斑变性
|
Roche
|
Phase II
|
11.22
|
|
Evolocumab
|
Anti-PCSK9单抗
|
高血脂
|
Amgen
|
Phase III
|
10.93
|
|
Alirocumab
|
Anti-PCSK9单抗
|
高血脂
|
Sanofi
|
Phase III
|
10.48
|
|
Plegridy
|
干扰素β-1a
|
多发性硬化症
|
Biogen Idec
|
Filed
|
10.47
|
|
Secukinumab
|
Anti-IL-17单抗
|
银屑病
|
Novartis
|
Filed
|
10.30
|
|
MEDI4736
|
Anti-PDL1单抗
|
肿瘤
|
AstraZeneca
|
Phase III
|
9.67
|
|
Ocrelizumab
|
Anti-CD20单抗
|
类风湿性关节炎
|
Roche
|
Phase III
|
8.94
|
|
Abemaciclib
|
CDK4/6抑制剂
|
HER2阴性乳腺癌
|
Eli Lilly
|
Phase III
|
6.51
|
Ref:
EvaluatePharma, World Preview 2014, Outlook to 2020
|
